Citi Starts Acumen Pharmaceuticals, Inc. (ABOS) at Buy, 'Targeting Amyloid Beta Oligomers as a Differentiated Strategy in Alzheimer’s'
Tweet Send to a Friend
Citi analyst David Hoang initiates coverage on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) with a Buy rating and a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
